Safety of MR liver specific contrast media

• Published in: European radiology Vol. 15; no. 8; pp. 1607 - 1614
• Main Authors: Bellin, Marie-France, Webb, Judith A W, Van Der Molen, Aart J, Thomsen, Henrik S, Morcos, Sameh K
• Format: Journal Article
• Language: English
• Published: Germany Springer Nature B.V 01.08.2005
• Subjects: Biliary Tract Diseases - diagnosis; Clinical trials; Contrast agents; Contrast media; Contrast Media - adverse effects; Dextrans; Ferrosoferric Oxide; Gadolinium; Gadolinium - adverse effects; Guidelines; Humans; Iron - adverse effects; Iron oxides; Literature reviews; Liver; Liver - anatomy & histology; Liver - drug effects; Liver Diseases - diagnosis; Magnetic resonance; Magnetic Resonance Imaging; Magnetite Nanoparticles; Manganese; Manganese - adverse effects; Oxides - adverse effects; Radiology; Safety
• ISSN: 0938-7994; 1432-1084
• DOI: 10.1007/s00330-004-2612-x

Over the past few years a number of magnetic resonance (MR) liver specific contrast agents have been introduced. In this report the safety issues of these agents are addressed. A literature search was carried out. Based on the available information, simple guidelines on the safety issue of liver specific contrast agents have been produced by the Contrast Media Safety Committee of the European Society of Urogenital Radiology. The report and guidelines were discussed at the 11th European Symposium on Urogenital Radiology in Santiago de Compostela. Liver specific contrast agents appear in general to be safe and well tolerated. However, the incidence of adverse reactions with iron oxides and the intravenous manganese based agent seems to be slightly higher than with gadolinium based agents. However, no safety information from comparative clinical trials has been published. Guidelines on the safety aspects are presented.